Medullary Thyroid Cancer-Pipeline Review, H1 2016

Medullary Thyroid Cancer-Pipeline Review, H1 2016


  • Products Id :- GMDHC7748IDB
  • |
  • Pages: 97
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Medullary Thyroid Cancer-Pipeline Review, H1 2016', provides an overview of the Medullary Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer

The report reviews pipeline therapeutics for Medullary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Medullary Thyroid Cancer therapeutics and enlists all their major and minor projects

The report assesses Medullary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Medullary Thyroid Cancer

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Medullary Thyroid Cancer Overview 7

Therapeutics Development 8

Pipeline Products for Medullary Thyroid Cancer-Overview 8

Pipeline Products for Medullary Thyroid Cancer-Comparative Analysis 9

Medullary Thyroid Cancer-Therapeutics under Development by Companies 10

Medullary Thyroid Cancer-Therapeutics under Investigation by Universities/Institutes 11

Medullary Thyroid Cancer-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Medullary Thyroid Cancer-Products under Development by Companies 14

Medullary Thyroid Cancer-Products under Investigation by Universities/Institutes 15

Medullary Thyroid Cancer-Companies Involved in Therapeutics Development 16

Advenchen Laboratories, LLC 16

Ariad Pharmaceuticals, Inc. 17

Boehringer Ingelheim GmbH 18

Celgene Corporation 19

Hutchison MediPharma Limited 20

Immunomedics, Inc. 21

Nerviano Medical Sciences S.r.l. 22

Novartis AG 23

Medullary Thyroid Cancer-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

AL-3818-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

CLM-29-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

CLM-94-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

everolimus-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

GI-6207-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

HMPL-012-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

nintedanib-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

NMS-616-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

pasireotide-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

ponatinib hydrochloride-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Pz-1-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

TF-2-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Medullary Thyroid Cancer-Recent Pipeline Updates 64

Medullary Thyroid Cancer-Dormant Projects 92

Medullary Thyroid Cancer-Discontinued Products 93

Medullary Thyroid Cancer-Product Development Milestones 94

Featured News & Press Releases 94

Apr 08, 2013: Ariad Pharma Presents New Preclinical Data On Ponatinib At AACR Annual Meeting 2013 94

Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 94

Appendix 96

Methodology 96

Coverage 96

Secondary Research 96

Primary Research 96

Expert Panel Validation 96

Contact Us 96

Disclaimer 97

List of Figures

Number of Products under Development for Medullary Thyroid Cancer, H1 2016 8

Number of Products under Development for Medullary Thyroid Cancer-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 13

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Top 10 Targets, H1 2016 25

Number of Products by Stage and Top 10 Targets, H1 2016 25

Number of Products by Top 10 Mechanism of Actions, H1 2016 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27

Number of Products by Routes of Administration, H1 2016 29

Number of Products by Stage and Routes of Administration, H1 2016 29

Number of Products by Molecule Types, H1 2016 31

Number of Products by Stage and Molecule Types, H1 2016 31

List of Tables

Number of Products under Development for Medullary Thyroid Cancer, H1 2016 8

Number of Products under Development for Medullary Thyroid Cancer-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 12

Comparative Analysis by Early Stage Development, H1 2016 13

Products under Development by Companies, H1 2016 14

Products under Investigation by Universities/Institutes, H1 2016 15

Medullary Thyroid Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2016 16

Medullary Thyroid Cancer-Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 17

Medullary Thyroid Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2016 18

Medullary Thyroid Cancer-Pipeline by Celgene Corporation, H1 2016 19

Medullary Thyroid Cancer-Pipeline by Hutchison MediPharma Limited, H1 2016 20

Medullary Thyroid Cancer-Pipeline by Immunomedics, Inc., H1 2016 21

Medullary Thyroid Cancer-Pipeline by Nerviano Medical Sciences S.r.l., H1 2016 22

Medullary Thyroid Cancer-Pipeline by Novartis AG, H1 2016 23

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Stage and Target, H1 2016 26

Number of Products by Stage and Mechanism of Action, H1 2016 28

Number of Products by Stage and Route of Administration, H1 2016 30

Number of Products by Stage and Molecule Type, H1 2016 32

Medullary Thyroid Cancer Therapeutics-Recent Pipeline Updates, H1 2016 64

Medullary Thyroid Cancer-Dormant Projects, H1 2016 92

Medullary Thyroid Cancer-Discontinued Products, H1 2016 93

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advenchen Laboratories, LLC

Ariad Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Celgene Corporation

Hutchison MediPharma Limited

Immunomedics, Inc.

Nerviano Medical Sciences S.r.l.

Novartis AG

Medullary Thyroid Cancer Therapeutic Products under Development, Key Players in Medullary Thyroid Cancer Therapeutics, Medullary Thyroid Cancer Pipeline Overview, Medullary Thyroid Cancer Pipeline, Medullary Thyroid Cancer Pipeline Assessment

select a license

Single User License
USD 2000 INR 129160
Site License
USD 4000 INR 258320
Corporate User License
USD 6000 INR 387480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com